Completed PHASE2 INTERVENTIONAL NCT00001365

Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System

NMDA Receptor Antagonist Treatment of Neurodegenerative Disease

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Conditions Neurodegenerative Disease Parkinson's Disease

Updated 5 times since 2017 Last updated: Jul 12, 2006 Started: Jul 31, 1993 Completion: Jun 30, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Neurodegenerative Disease and Parkinson's Disease and is currently completed. National Institute of Neurological Disorders and Stroke (NINDS) leads this study, which shows 5 recorded versions since 1993 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 1993

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Neurological Disorders and Stroke (NINDS)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States